Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy
Andrea Gramegna, Massimiliano Ruscica, Gloria Leonardi, Chiara Macchi, Isabella Fichtner, Gianmarco Putti, Margherita Carnevale Schianca, Leonardo Terranova, Gianfranco Alicandro, Francesco Blasi
Topics & Concepts
IvacaftorCystic fibrosisMedicineInternal medicineCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesAsthma and respiratory diseasesInhalation and Respiratory Drug Delivery